Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Figure 1

Randomized controlled trial and open-label extension study designs.aNonresponders (<20% improvement in tender or swollen joint counts in 28 joints) were eligible to receive an additional 30-minute infusion of 80-mg tabalumab as a rescue dose at week 16. IV, Intravenous; MTX-IR, Methotrexate inadequate responders; n, Number of patients per treatment arm; N, Total number of patients enrolled; RCT, Randomized controlled trial; SC, Subcutaneous; TNF-IR, Tumor necrosis factor inadequate responders.

Back to article page